Gabriel Braley

Pfizer (United States) — United States

Medicine · Health Sciences

10h-index2.8kcitations11works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cannabis and Cannabinoid Research(7), Neurotransmitter Receptor Influence on Behavior(5), Neuroscience and Neuropharmacology Research(4), Neuroscience of respiration and sleep(3), Forensic Toxicology and Drug Analysis(2)

Publications11 total

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity
The International Journal of Neuropsychopharmacology·2020· 12 citedOpen Access
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Neuromuscular Disorders·2019· 602 citedOpen Access
Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects
International Journal of Clinical Pharmacology and Therapeutics·2014· 7 cited
Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans
The International Journal of Neuropsychopharmacology·2012· 27 cited
The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories
Psychopharmacology·2011· 33 cited
The effects of cannabinoids on serum cortisol and prolactin in humans
Psychopharmacology·2008· 117 citedOpen Access
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans
Psychopharmacology·2008· 121 citedOpen Access
Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis
Neuropsychopharmacology·2008· 260 citedOpen Access
Enhanced Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia
Neuropsychopharmacology·2006· 51 cited
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
Biological Psychiatry·2005· 604 cited
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
Neuropsychopharmacology·2004· 1.0k citedOpen Access

Frequent Co-authors

Deepak Cyril D’Souza(8), Edward Perry(7), Thomas B. Cooper(5), John H. Krystal(5), Mohini Ranganathan(5), Ralitza Gueorguieva(4), Brian Pittman(4), Zoran Zimolo(3), Steven Madonick(2), Kimberlee Forselius-Bielen(2), Savita G. Bhakta(2), Michelle Carbuto(2), R. Andrew Sewell(2), Lisa Macdougall(1), Yola Ammerman(1), Yu‐Te Wu(1), Walid Abi‐Saab(1), Anne Doersch(1), Darryl C. De Vivo(1), Enrico Bertini(1)